The presentation is titled “ BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results